Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 53, Issue 17, Pages 6361-6367Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm100487z
Keywords
-
Categories
Funding
- National Cancer Institute, National Institutes of Health [R01CA109025]
- Breast Cancer Research Foundation
- Susan G. Komen Foundation
- University of Michigan Cancer Center [P30CA046592]
Ask authors/readers for more resources
A series of compounds were designed and synthesized as antagonists of cIAP-1/2 and XIAP based upon our previously identified lead compound SM-122 (1). The most potent of these (7) binds to XIAP, cIAP-1, and cIAP-2 proteins with K(i) values of 36, <1, and <1.9 nM, respectively. Consistent with its potent binding affinities to IAPs, 7 effectively antagonizes XIAP in a cell-free caspase-9 functional assay, efficiently induces cIAP-1 degradation in cells at concentrations as low as 10 nM, and triggers activation of caspases and PARP cleavage in the MDA-MB-231 breast cancer cell line. Compound 7 potently inhibits cell growth in the MDA-MB-231 cancer cell line with an IC(50) value of 200 nM and is 9 times more potent than compound 1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available